Mersana Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Mersana Therapeutics has a total shareholder equity of $36.9M and total debt of $25.2M, which brings its debt-to-equity ratio to 68.4%. Its total assets and total liabilities are $226.1M and $189.2M respectively.
Key information
68.4%
Debt to equity ratio
US$25.23m
Debt
Interest coverage ratio | n/a |
Cash | US$209.08m |
Equity | US$36.90m |
Total liabilities | US$189.16m |
Total assets | US$226.06m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0M4's short term assets ($214.1M) exceed its short term liabilities ($63.6M).
Long Term Liabilities: 0M4's short term assets ($214.1M) exceed its long term liabilities ($125.5M).
Debt to Equity History and Analysis
Debt Level: 0M4 has more cash than its total debt.
Reducing Debt: 0M4's debt to equity ratio has increased from 0% to 68.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0M4 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 0M4 has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 16.8% each year.